Autres langues Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L1008

Temps Différé Nasdaq Autres places de cotation 15:30:00 02/07/2024			Varia. 5j.	Varia. 1 janv.
0,45 ^USD	0,00 %		-11,01 %	-55,88 %

31/05	Lipella Pharmaceuticals Inc. annonce l'achèvement de la visite d'initiation du site pour l'essai de phase 2A du LP-310 dans le lichen plan buccal	CI
09/05	Lipella Pharmaceuticals Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus	31/05
Lipella Pharmaceuticals Inc. Announces Completion of Site Initiation Visit for Phase 2A Trial of LP-310 in Oral Lichen Planus	31/05
Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	29/05
Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b	21/05
Lipella Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise	17/04
Lipella Pharmaceuticals Inc. Appoints Jason Hafron and Pradeep Tyagi to Scientific Advisory Board	17/04
Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024	05/04
Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis	03/04
PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease	07/03
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03
Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline	05/03
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/02
Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference	20/02
Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished	20/12
Wall Street Set to Open Lower Friday; Employment Growth Tops Forecasts	08/12
Top Premarket Decliners	08/12
Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
Lipella Gets FDA Orphan Designation for LP-310 in Oral Graft-vs-Host Disease	10/11
FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease	10/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Lipella Pharmaceuticals Inc.

Actions

LIPO

US53630L1008

Autres langues

Filtres